𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia

✍ Scribed by Kosei Matsue; Masami Takeuchi; Mihoko Koseki; Hidetaka Uryu

Publisher
Springer
Year
2006
Tongue
English
Weight
104 KB
Volume
85
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Secondary myelodysplastic syndrome in a
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
✍ Arturo Vega-Ruiz; Susan O’Brien; Jorge Cortes; Partow Kebriaei; Deborah Thomas; πŸ“‚ Article πŸ“… 2008 πŸ› Elsevier Science 🌐 English βš– 90 KB

The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in c

The extent of minimal residual disease r
The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
✍ Seok Lee; Yoo-Jin Kim; Nak-Gyun Chung; Jihyang Lim; Dong-Gun Lee; Hee-Je Kim; Ch πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 445 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph‐positive ALL). Here, the authors analyzed for risk factors that af